Inhibitex announces that 100 mg INX-189 in combination with RBV was well tolerated and no adverse events; extension of Phase 1b trial; offering of 1.95 mln shares (INHX) 11.40 : The co reported top-line safety and antiviral data from an ongoing Phase 1b extension trial of INX-189. In the ongoing trial, 100 mg INX-189 continued to demonstrate potent and dose-dependent synergistic antiviral activity with a median HCV RNA reduction from baseline. Further, 100 mg INX-189 in combination with RBV was well tolerated and there were no serious adverse events. In this same clinical trial, the co also reported antiviral data indicating that INX-189, when dosed once-daily at 9 and 25 mg in combination with RBV for seven days, demonstrated dose-dependent, synergistic antiviral activity. The co also reported today that, subject to regulatory review, it plans to further expand its ongoing Phase 1b extension trial. The co anticipates that the Phase 1b extension trial will be completed in the first quarter of 2012. Additionally, the Company reported that it plans to submit a protocol amendment this quarter to its ongoing Phase 2 study in genotype 2 and 3 HCV-infected patients to include the evaluation of 100 mg and 200 mg of INX-189 dosed once-daily in combination with RBV for 12 weeks. The Company reported today that it had recently sold a total of 1,949,015 shares of common.
(Dow Jones) In the wake of recent Hepatitis C drug data and the planned $11B acquisition of Pharmasset (VRUS), William Blair upgrades Idenix (IDIX) to outperform and more than doubles its price target on it and Inhibitex (INHX). The investment bank notes "nukes are hot," as in the class of medicines called nucleotide analogs that small studies in certain patients have shown yield high rates of cure in just 12 weeks, and with fewer side effects than existing treatments. William Blair says IDIX and INHX are likely buyout candidates of their own the next year as big drug makers "will be highly interested in the nuke assets to compete effectively" against Gilead (GILD), which is buying VRUS. IDIX and INHX are inactive premarket
(Dow Jones) In the wake of recent Hepatitis C drug data and the planned $11B acquisition of Pharmasset (VRUS), William Blair upgrades Idenix (IDIX) to outperform and more than doubles its price target on it and Inhibitex (INHX). The investment bank notes "nukes are hot," as in the class of medicines called nucleotide analogs that small studies in certain patients have shown yield high rates of cure in just 12 weeks, and with fewer side effects than existing treatments. William Blair says IDIX and INHX are likely buyout candidates of their own the next year as big drug makers "will be highly interested in the nuke assets to compete effectively" against Gilead (GILD), which is buying VRUS. IDIX and INHX are inactive premarket
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
